MX2018002048A - Anticuerpos inhibidores de via del factor tisular y usos de los mismos. - Google Patents

Anticuerpos inhibidores de via del factor tisular y usos de los mismos.

Info

Publication number
MX2018002048A
MX2018002048A MX2018002048A MX2018002048A MX2018002048A MX 2018002048 A MX2018002048 A MX 2018002048A MX 2018002048 A MX2018002048 A MX 2018002048A MX 2018002048 A MX2018002048 A MX 2018002048A MX 2018002048 A MX2018002048 A MX 2018002048A
Authority
MX
Mexico
Prior art keywords
tissue factor
pathway inhibitor
factor pathway
inhibitor antibodies
antibodies
Prior art date
Application number
MX2018002048A
Other languages
English (en)
Inventor
Pittman Debra
Zong Sean Juo
R Apgar James
BENARD Susan
J Carven Gregory
R Hett Sunita
HOLSTI Matthew
Jasuja Reema
Jin Macy
Stahl Mark
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MX2018002048A publication Critical patent/MX2018002048A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La invención se refiere a anticuerpos, y fragmentos de unión a antígeno del mismo, que se unen de manera específica al TFPI e inhiben una actividad del mismo; dichos anticuerpos y fragmentos son útiles para tratar trastornos hemorrágicos y reducir el tiempo de coagulación.
MX2018002048A 2015-08-19 2016-08-10 Anticuerpos inhibidores de via del factor tisular y usos de los mismos. MX2018002048A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562207229P 2015-08-19 2015-08-19
US201662360205P 2016-07-08 2016-07-08
PCT/IB2016/054814 WO2017029583A2 (en) 2015-08-19 2016-08-10 Tissue factor pathway inhibitor antibodies and uses thereof

Publications (1)

Publication Number Publication Date
MX2018002048A true MX2018002048A (es) 2018-04-13

Family

ID=56894019

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018002048A MX2018002048A (es) 2015-08-19 2016-08-10 Anticuerpos inhibidores de via del factor tisular y usos de los mismos.
MX2022004834A MX2022004834A (es) 2015-08-19 2018-02-16 Anticuerpos inhibidores de via del factor tisular y usos de los mismos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022004834A MX2022004834A (es) 2015-08-19 2018-02-16 Anticuerpos inhibidores de via del factor tisular y usos de los mismos.

Country Status (21)

Country Link
US (4) US10550200B2 (es)
EP (1) EP3337827A2 (es)
JP (4) JP6664467B2 (es)
KR (4) KR102068915B1 (es)
CN (2) CN114163531A (es)
AU (2) AU2016307967C1 (es)
BR (1) BR112018001478A2 (es)
CA (2) CA2939010A1 (es)
CO (1) CO2018001473A2 (es)
IL (3) IL289766B2 (es)
MX (2) MX2018002048A (es)
MY (1) MY195443A (es)
NZ (1) NZ739871A (es)
PE (2) PE20180556A1 (es)
PH (1) PH12018500211A1 (es)
RU (1) RU2705540C2 (es)
SA (1) SA518390944B1 (es)
SG (1) SG10201912817YA (es)
TW (1) TWI640538B (es)
WO (1) WO2017029583A2 (es)
ZA (1) ZA201800453B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2379600B2 (en) † 2008-12-22 2020-10-14 Novo Nordisk A/S Antibodies against tissue factor pathway inhibitor
CA3101298A1 (en) 2010-03-01 2011-09-09 Bayer Healthcare Llc Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
NZ739871A (en) * 2015-08-19 2022-05-27 Pfizer Tissue factor pathway inhibitor antibodies and uses thereof
KR102337683B1 (ko) * 2018-09-21 2021-12-13 주식회사 녹십자 고효율 항-tfpi 항체 조성물
JP7289913B2 (ja) * 2018-10-11 2023-06-12 ファイザー・インク Ｔｆｐｉアンタゴニストのための投薬レジメン
CN112442127A (zh) * 2019-08-29 2021-03-05 苏州康宁杰瑞生物科技有限公司 针对tfpi的单克隆抗体
EP4031569A4 (en) * 2019-09-16 2023-10-18 Opsidio, LLC ANTI-STEM CELL FACTOR ANTIBODIES AND METHODS OF USE THEREOF
WO2021094917A1 (en) * 2019-11-13 2021-05-20 Pfizer Inc. Stable aqueous anti-tfpi antibody formulation
KR102140653B1 (ko) 2020-01-13 2020-08-03 이선재 떡 연속증숙장치
WO2021231982A1 (en) * 2020-05-14 2021-11-18 City Of Hope Smc1a antibodies and uses thereof
JP2023547499A (ja) * 2020-11-06 2023-11-10 ノバルティス アーゲー 抗体Ｆｃ変異体
CN113325185B (zh) * 2021-07-09 2024-04-19 重庆鼎润医疗器械有限责任公司 多水平质控品及其制备方法和在血栓弹力图检测上的应用
WO2023118150A1 (en) 2021-12-22 2023-06-29 Royal College Of Surgeons In Ireland A conjugate for use in localising a molecule to the vascular endothelium.
CN117285632A (zh) * 2022-06-17 2023-12-26 安源医药科技（上海）有限公司 针对tfpi的单克隆抗体及其用途
CN116903739B (zh) * 2023-03-28 2023-12-15 中国人民解放军军事科学院军事医学研究院 一种抗s100b蛋白的抗体及其应用

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4754065A (en) 1984-12-18 1988-06-28 Cetus Corporation Precursor to nucleic acid probe
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US5422120A (en) 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
JP2752788B2 (ja) 1989-01-23 1998-05-18 カイロン コーポレイション 感染および過剰増殖障害の為の組換え療法
US6673776B1 (en) 1989-03-21 2004-01-06 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human
EP1026253B2 (en) 1989-03-21 2012-12-19 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
EP0487587A1 (en) 1989-08-18 1992-06-03 Chiron Corporation Recombinant retroviruses delivering vector constructs to target cells
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
ZA911974B (en) 1990-03-21 1994-08-22 Res Dev Foundation Heterovesicular liposomes
CA2115742A1 (en) 1991-08-20 1993-03-04 Ronald G. Crystal Adenovirus mediated transfer of genes to the gastrointestinal tract
WO1993010218A1 (en) 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vectors including foreign genes and negative selective markers
GB9125623D0 (en) 1991-12-02 1992-01-29 Dynal As Cell modification
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
EP0650370A4 (en) 1992-06-08 1995-11-22 Univ California METHODS AND COMPOSITIONS TARGETED ON SPECIFIC TISSUES.
EP0644946A4 (en) 1992-06-10 1997-03-12 Us Health VECTOR PARTICLES RESISTANT TO HUMAN SERUM INACTIVATION.
GB2269175A (en) 1992-07-31 1994-02-02 Imperial College Retroviral vectors
AU680459B2 (en) 1992-12-03 1997-07-31 Genzyme Corporation Gene therapy for cystic fibrosis
JP3545403B2 (ja) 1993-04-22 2004-07-21 スカイファルマ インコーポレイテッド 医薬化合物を被包しているシクロデキストリンリポソーム及びその使用法
JP3532566B2 (ja) 1993-06-24 2004-05-31 エル． グラハム，フランク 遺伝子治療のためのアデノウイルスベクター
WO1995007994A2 (en) 1993-09-15 1995-03-23 Viagene, Inc. Recombinant alphavirus vectors
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
DE69434594T2 (de) 1993-10-25 2006-09-21 Canji, Inc., San Diego Rekombinante adenoviren-vektor und verfahren zur verwendung
KR100241300B1 (ko) 1993-11-16 2000-03-02 Sheldon A. Schaffer 활성물질의 조절된 방출성을 갖는 소포
US6436908B1 (en) 1995-05-30 2002-08-20 Duke University Use of exogenous β-adrenergic receptor and β-adrenergic receptor kinase gene constructs to enhance myocardial function
WO1995030763A2 (en) 1994-05-09 1995-11-16 Chiron Viagene, Inc. Retroviral vectors having a reduced recombination rate
WO1996017072A2 (en) 1994-11-30 1996-06-06 Chiron Viagene, Inc. Recombinant alphavirus vectors
AU2998597A (en) 1996-05-06 1997-11-26 Chiron Corporation Crossless retroviral vectors
WO1999018792A1 (en) 1997-10-10 1999-04-22 Johns Hopkins University Gene delivery compositions and methods
JP4340339B2 (ja) * 1998-07-31 2009-10-07 財団法人化学及血清療法研究所 血液凝固因子もしくは血液凝固制御因子欠損モデル動物並びに該モデル動物の作製方法
DE60226641D1 (de) 2001-12-03 2008-06-26 Amgen Fremont Inc Antikörperkategorisierung auf der grundlage von bindungseigenschaften
PT2270048E (pt) 2002-12-24 2016-02-10 Rinat Neuroscience Corp Anticorpos anti-ngf e métodos de utilização dos mesmos
EP1997830A1 (en) * 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
AU2007358045A1 (en) * 2007-08-23 2009-02-26 Lfb Biotechnologies Anti-idiotypic antibodies which neutralise the inhibitory activity of an inhibitory antibody directed against the C1 domain of factor VIII
FR2933908B1 (fr) 2008-07-16 2010-12-24 Renault Sas Dispositif de protection pour une porte de vehicule automobile.
UA112050C2 (uk) 2008-08-04 2016-07-25 БАЄР ХЕЛСКЕР ЛЛСі Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
JP5739816B2 (ja) * 2008-12-19 2015-06-24 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ Ｔｆｐｉインヒビターおよび使用法
EP2379600B2 (en) * 2008-12-22 2020-10-14 Novo Nordisk A/S Antibodies against tissue factor pathway inhibitor
WO2010072687A1 (en) 2008-12-22 2010-07-01 Novo Nordisk A/S Antibodies against tissue factor pathway inhibitor (tfpi)
EP3708190A1 (en) 2010-02-26 2020-09-16 Novo Nordisk A/S Stable antibody containing compositions
CA3101298A1 (en) 2010-03-01 2011-09-09 Bayer Healthcare Llc Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
WO2011115712A2 (en) * 2010-03-19 2011-09-22 Baxter International Inc Tfpi inhibitors and methods of use
US20130136733A1 (en) 2010-05-28 2013-05-30 Novo Nordisk A/S Stable Multi-Dose Compositions Comprising an Antibody and a Preservative
EP2588499B1 (en) * 2010-06-30 2020-04-08 Novo Nordisk A/S Antibodies that are capable of specifically binding tissue factor pathway inhibitor
EA034214B1 (ru) * 2011-04-01 2020-01-17 Байер Хелфкеа Ллк Выделенное моноклональное антитело или его антигенсвязывающий фрагмент, который связывается с эпитопом ингибитора пути тканевого фактора человека, содержащая его фармацевтическая композиция, способ применения этой композиции и кодирующая антитело молекула нуклеиновой кислоты
CN103890246A (zh) 2011-08-18 2014-06-25 亲和生物科学公司 可溶性多肽
BR112014024373A2 (pt) 2012-03-30 2017-08-08 Bayer Healthcare Llc anticorpos regulados por protease
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
JP2016514687A (ja) 2013-03-15 2016-05-23 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ 組織因子経路インヒビターに対するプロドラッグ抗体
ES2926773T3 (es) 2013-03-15 2022-10-28 Novo Nordisk As Anticuerpos capaces de unirse específicamente a dos epítopos en el inhibidor de la ruta del factor tisular
PL2970497T3 (pl) 2013-03-15 2018-05-30 Bayer Healthcare Llc Warianty przeciwciał anty-TFPI z różnicowym wiązaniem w zakresie pH dla poprawy farmakokinetyki
US10457743B2 (en) 2013-07-19 2019-10-29 Novo Nordisk A/S Antibodies recognizing the N-terminal part of tissue factor pathway inhibitor capable of eliciting pro-coagulant activity
CN107001437B (zh) 2014-11-27 2021-10-29 公立大学法人横滨市立大学 卵巢透明细胞腺癌的检查方法及检查药
BR112017018328A2 (pt) 2015-02-25 2018-07-10 Mogam Institute For Biomedical Research anticorpo de ligação ao tfpi, método para produzir e composição compreendendo o mesmo
NZ739871A (en) * 2015-08-19 2022-05-27 Pfizer Tissue factor pathway inhibitor antibodies and uses thereof
JP7289913B2 (ja) 2018-10-11 2023-06-12 ファイザー・インク Ｔｆｐｉアンタゴニストのための投薬レジメン

Also Published As

Publication number Publication date
US10875929B2 (en) 2020-12-29
BR112018001478A2 (pt) 2018-09-18
US11634504B2 (en) 2023-04-25
IL256913A (en) 2018-03-29
US20170073428A1 (en) 2017-03-16
MX2022004834A (es) 2022-05-16
CN114163531A (zh) 2022-03-11
KR102438650B1 (ko) 2022-08-31
EP3337827A2 (en) 2018-06-27
JP6664467B2 (ja) 2020-03-13
KR102068915B1 (ko) 2020-01-22
IL289766B1 (en) 2023-06-01
AU2016307967B2 (en) 2022-02-17
CA2939010A1 (en) 2017-02-19
KR102068915B9 (ko) 2023-10-12
JP2022084623A (ja) 2022-06-07
IL302353A (en) 2023-06-01
PH12018500211A1 (en) 2018-08-13
KR20190097319A (ko) 2019-08-20
RU2018104283A (ru) 2019-09-19
IL289766A (en) 2022-03-01
US10550200B2 (en) 2020-02-04
WO2017029583A3 (en) 2017-07-20
CN107922506B (zh) 2021-11-09
KR20220136381A (ko) 2022-10-07
CA3174958A1 (en) 2017-02-19
KR20180030936A (ko) 2018-03-26
US20200190214A1 (en) 2020-06-18
SG10201912817YA (en) 2020-02-27
JP2018527922A (ja) 2018-09-27
JP2024054266A (ja) 2024-04-16
US20230416405A1 (en) 2023-12-28
MY195443A (en) 2023-01-21
TW201718659A (zh) 2017-06-01
WO2017029583A2 (en) 2017-02-23
IL256913B (en) 2022-02-01
JP2020096627A (ja) 2020-06-25
PE20240142A1 (es) 2024-02-01
SA518390944B1 (ar) 2022-02-08
KR102536303B1 (ko) 2023-05-26
JP7303761B2 (ja) 2023-07-05
AU2016307967C1 (en) 2023-10-05
AU2016307967A1 (en) 2018-02-01
ZA201800453B (en) 2018-12-19
CO2018001473A2 (es) 2018-05-10
IL289766B2 (en) 2023-10-01
US20210101998A1 (en) 2021-04-08
PE20180556A1 (es) 2018-04-02
TWI640538B (zh) 2018-11-11
AU2022201091A1 (en) 2022-03-10
RU2705540C2 (ru) 2019-11-07
CN107922506A (zh) 2018-04-17
KR20230074843A (ko) 2023-05-31
RU2018104283A3 (es) 2019-09-19
NZ739871A (en) 2022-05-27

Similar Documents

Publication Publication Date Title
SA518390944B1 (ar) أجسام مضادة لمثبط مسار عامل نسيج واستخداماتها
PH12018500714A1 (en) Anti-tigit antigen-binding proteins and methods of use thereof
EA201890834A1 (ru) Агонистические антитела, специфически связывающие человеческий cd40, и способы их применения
JOP20160131B1 (ar) الأجسام المضادة للعامل xi وطرق الاستخدام
MX2018008105A (es) Compuestos inhibidores de metaloenzima.
NZ742742A (en) Compositions and methods for inhibiting arginase activity
MX2018008052A (es) Inhibidores de desmetilasa especifica de lisina 1 (lsd1).
EA201891251A1 (ru) Бициклические ингибиторы pad4
JO3701B1 (ar) مضادات حيوية بشرية لمتلازمة الشرق الأوسط التنفسية - بروتين كورونا فيروس الشوكي
NZ766356A (en) Anti-pd-1 antibodies
EA201691470A1 (ru) Белки, связывающие калликреин плазмы, и их применение для лечения наследственного ангионевротического отека
NZ727020A (en) Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
BR112016022855A2 (pt) composições e métodos para modular a expressão de pkk
SG10201808940WA (en) Nox inhibitor and nfкb inhibitor containing methoxyflavone
EA201690007A1 (ru) Соединения, ингибирующие металлоферменты
MX2020006365A (es) Quinazolinonas como inhibidores de poli(adenosin difosfato-ribosa)polimerasa 14 (parp14).
MX2022007436A (es) Inhibidores de la autotaxina y sus usos.
MX2018006700A (es) Inhibidores aza-bencimidazol de peptidilarginina desiminasa (pad4).
MX2018009325A (es) Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn).
MX2019013808A (es) Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cancer.
MX2015011518A (es) Agentes de enlace de met y usos de los mismos.
PH12015501360A1 (en) Bmp-6 antibodies
EA201792561A1 (ru) Антитела, нацеленные на морфогенетический белок кости 9 (bmp9), и способы их применения
MX2019009498A (es) Anticuerpos mimeticos de fgf21 y usos de los mismos.
EA202191471A1 (ru) Противовоспалительные полипептиды